Business Context and Reporting Period
This Form 8-K filing by REGENXBIO Inc. (REGENXBIO) covers events occurring on October 2, 2017. The report details the termination of a previously announced merger agreement with Dimension Therapeutics, Inc. (Dimension).
Key Financial Metrics
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed is a one-time transactional payment.
- Termination Fee Received: $2.85 million paid by Dimension to REGENXBIO pursuant to the Merger Agreement.
Material Changes
The primary material change is the dissolution of the strategic acquisition plan:
- Merger Termination: On October 2, 2017, Dimension terminated the Merger Agreement originally signed on August 24, 2017.
- Reason for Termination: Dimension's Board of Directors determined that a revised proposal from Ultragenyx Pharmaceutical Inc. to acquire Dimension for $6.00 per share in cash constituted a "superior proposal."
- Matching Rights: REGENXBIO was granted a matching right under the agreement but elected not to increase its consideration and formally waived this right, leading to the termination.
Outlook, Risks, and Management Commentary
Management responded to the termination by issuing a press release on October 2, 2017, which is filed as Exhibit 99.1. The filing indicates that REGENXBIO will not pursue the acquisition of Dimension following the superior proposal from a third party. No specific forward-looking guidance regarding future revenue or operational plans is included in this specific report.
Key Facts for Investor Verification
- Verify the receipt and accounting treatment of the $2.85 million termination fee in upcoming financial statements.
- Confirm the status of Dimension Therapeutics' acquisition by Ultragenyx Pharmaceutical Inc.
- Review the full text of the press release (Exhibit 99.1) for any additional strategic commentary from REGENXBIO management.
- Note that this filing does not contain quarterly or annual financial performance data.